Oncology Brothers: Practice-Changing Cancer Discussions Multiple Myeloma ASH 2024 Highlights with Dr. Robert Orlowski
Jan 7, 2025
Dr. Robert Orlowski, an expert in multiple myeloma from MD Anderson Cancer Center, joins the discussion on groundbreaking ASH 2024 research. They explore the AQUILA study revealing early daratumumab intervention benefits, and a meta-analysis promoting quadruplet therapy as the new standard. The benefits of CAR-T therapy for lenalidomide-refractory patients are also highlighted. Furthermore, the use of IVIG alongside BCMA-targeted therapies shows promise in reducing infections and improving survival rates. Tune in for vital insights on the future of myeloma treatment!
AI Snips
Chapters
Transcript
Episode notes
Daratumumab Benefits Smoldering Myeloma
- Early intervention with daratumumab in high-risk smoldering myeloma significantly improves progression-free survival.
- There is a promising trend toward better overall survival though longer follow-up is needed.
Approach High-Risk Smoldering Myeloma
- Monitor high-risk smoldering myeloma closely with advanced imaging like whole-body MRI.
- Treat patients with rising markers or symptoms using daratumumab or lenalidomide if not in clinical trials.
Quadruplet Therapy Upfront Improves Survival
- Quadruplet therapy with anti-CD38 antibodies upfront improves both progression-free and overall survival in newly diagnosed myeloma.
- Using all effective drugs early yields better outcomes than reserving them for relapse.